Clinical trials: Patients
HIV Infections
Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic…
- Trial name
- COOL (NCT00643968)
- Testing
- EFV+TDF, EFV+3TC+TDF
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).
- Conditions
- Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms
- Trial name
- NCT02837991
- Testing
- CDX-014
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celldex Therapeutics
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
Poor Ovarian Response
Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET
Observe the clinical efficacy and safety of Recombinant Human Growth Hormone Injection assisted in the treatment of the patients with poor ovarian response in vitro fertilization and embryo transfer.
- Trial name
- NCT02801591
- Testing
- Conventional ovarian stimulation proctol without rhGH
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
COPD
Therapeutic Effect of PBF-680 in Patients With COPD
The purpose of the study is to investigate the effect of PBF-680 on the chronic inflammation and the lung function of patients with COPD on top of the standard medication.
- Trial name
- Respire (NCT05262218)
- Testing
- PBF-680 10mg
- Where
- 7 sites in Spain
- Volunteers
- 174 people
- Sponsor
- Palobiofarma SL
Carcinoma, Ovarian Neoplasm
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Our hypothesis is: the nutritional supplement Ocoxin-viusid improves the quality of life of patients, including a better tolerance to neoadjuvant chemotherapy.
- Conditions
- Carcinoma, Ovarian Neoplasm, Endocrine Gland Neoplasm, Urogenital Neoplasms
- Trial name
- NCT03562897
- Testing
- Ocoxin-Viusid
- Where
- Cuba
- Volunteers
- 40 people
- Sponsor
- Catalysis SL
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Tricuspid Regurgitation, Tricuspid Insufficiency
Transcatheter Repair of Tricuspid Regurgitation With Edwards Cardioband TR System Post Market Study (TriBAND)
The purpose of the study is to assess the safety and the effectiveness of the Cardioband Tricuspid Reconstruction System.
- Trial name
- TriBAND (NCT03779490)
- Testing
- Transcatheter Tricuspid Valve Repair
- Where
- 14 sites in Germany, Spain and 1 more
- Volunteers
- 150 people
- Sponsor
- Edwards Lifesciences
Thrombocytopenia, Neutropenia
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
This research study will investigate the safety and effectiveness of two different dose levels of a new, unapproved drug to be given along with the chemotherapy regimens gemcitabine and carboplatin or gemcitabine and cisplatin…
- Conditions
- Thrombocytopenia, Neutropenia, Lymphopenia, Anemia
- Trial name
- NCT00771810
- Testing
- TXA127
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Tarix Pharmaceuticals
Advanced Solid Tumors
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
This is a first-in-human, Phase I, multicenter, open label, dose escalation study to evaluate the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered IV in patients with any histologically…
- Trial name
- NCT03348514
- Testing
- CPX-POM - 30 mg/m^2, CPX-POM - 60 mg/m^2, CPX-POM - 120 mg/m^2
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- CicloMed LLC
Secondary Hyperparathyroidism
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder
The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney…
- Trial name
- NCT01414114
- Testing
- Etelcalcetide
- Volunteers
- 37 people
- Sponsor
- KAI Pharmaceuticals
Pulmonary Disease, Chronic Obstructive, COPD
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with COPD.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00396604
- Testing
- indacaterol maleate
- Where
- Belgium
- Volunteers
- 51 people
- Sponsor
- Novartis
Beta-Thalassemia
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with…
- Trial name
- NCT03381833
- Testing
- LJPC-401
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 84 people
- Sponsor
- La Jolla Pharmaceutical Company
Type 2 Diabetes Mellitus
Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients
The purpose of this study is to evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessment of AUC and Cmax of dapagliflozin
- Trial name
- NCT01055652
- Testing
- Dapagliflozin
- Where
- 2 sites in Japan
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Psoriasis
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
This study is a phase I, randomised, double blind (sponsor unblinded), placebo-controlled, single ascending dose study GSK2831781 administered by IV.
- Trial name
- NCT02195349
- Testing
- GSK2831781
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neoplasms
A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
This study will determine the maximum tolerated dose and the dose limiting toxicities (Part 1 of study) and the activity (Part 2 of study) of RO5126766 in patients with metastatic or advanced solid tumors.
- Trial name
- NCT00773526
- Testing
- RO5126766
- Where
- 3 sites in France, Spain and 1 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2, Dyslipidemia
Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia
The present study aims to assess the acceptability of a 4 week treatment of a new fixed-dose combination of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia
- Trial name
- NCT00490178
- Testing
- Fenofibrate 80 mg and metformin 1000 mg (fixed combination)
- Where
- 3 sites in France
- Volunteers
- 29 people
- Sponsor
- Solvay Pharmaceuticals
Breast Neoplasms
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab. The secondary objectives are safety and pharmacokinetic interaction
- Trial name
- NCT00386685
- Testing
- larotaxel (XRP9881), trastuzumab
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 51 people
- Sponsor
- Sanofi
Fabry Disease
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study.
- Trial name
- NCT02194985
- Testing
- migalastat HCl 150 mg
- Where
- 28 sites in United States, Argentina and 13 more
- Volunteers
- 84 people
- Sponsor
- Amicus Therapeutics
COVID-19
The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19
The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg versus placebo once daily administration with standard of care therapy for 14 days (maximum up to 21 days) in patients with moderate…
- Trial name
- NCT04347915
- Testing
- Clevudine
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Bukwang Pharmaceutical